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ORIGINAL ARTICLEEffectiveness and Safety of Oral
Anticoagulants in Patients With Nonvalvular
Atrial Fibrillation and Diabetes Mellitus
Gregory Y.H. Lip, MD; Allison V. Keshishian, MPH; Amiee L. Kang, MPH;
Xiaoyan Li, PhD; Amol D. Dhamane, MS; Xuemei Luo, PhD;
Neeraja Balachander, MD, PhD; Lisa Rosenblatt, MD, MPH; Jack Mardekian, PhD;
Anagha Nadkarni, PhD; Xianying Pan, MS; Manuela Di Fusco, MS;
Alessandra B. Garcia Reeves, MS, PhD; Huseyin Yuce, PhD;
and Steven B. Deitelzweig, MDAbstract
Objective: To address gaps in the data comparing nonevitamin K antagonist oral anticoagulants
(NOACs) and warfarin among patients with nonvalvular atrial fibrillation (NVAF) and diabetes.
Patients and Methods: A retrospective study was conducted on patients with NVAF and diabetes
newly initiating apixaban, dabigatran, rivaroxaban, or warfarin from January 1, 2013, through
September 30, 2015, with Medicare data from the US Centers for Medicare & Medicaid Services and 4
other US commercial claims databases. One-to-one propensity score matching was completed between
NOACs and warfarin and between NOACs in each database, and the results were pooled. Cox pro-
portional hazards models were used to evaluate the risk of stroke/systemic embolism (SE) and major
bleeding (MB).
Results: A total of 154,324 patients were included in the 6 matched cohorts, with a mean follow-up
time of 6 to 8 months. Compared with warfarin, apixaban (hazard ratio [HR], 0.67; 95% CI, 0.57-0.77)
and rivaroxaban (HR, 0.79; 95% CI, 0.71-0.89) were associated with a lower risk of stroke/SE; dabi-
gatran (HR, 0.84; 95% CI, 0.67-1.07) was associated with a similar risk of stroke/SE. Apixaban
(HR, 0.60; 95% CI, 0.56-0.65) and dabigatran (HR, 0.78; 95% CI, 0.69-0.88) were associated with a
lower risk of MB; rivaroxaban (HR, 1.02; 95% CI, 0.94-1.10) was associated with a similar risk of MB
compared with warfarin. Compared with dabigatran and rivaroxaban, apixaban was associated with a
lower risk of MB. Compared with rivaroxaban, dabigatran was associated with a lower risk of MB.
Conclusion: This studydthe largest observational study to date of patients with NVAF and diabetes
taking anticoagulantsdfound that NOACs were associated with variable rates of stroke/SE and MB
compared with warfarin.
Trial Registration: clinicaltrials.gov Identifier: NCT03087487
ª 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc. 2020;95(5):929-943From the Liverpool
Centre for Cardiovascular
Science at the Liverpool
Heart & Chest Hospital,
University of Liverpool,
Affiliations continued at
the end of this article.T here have been important develop-ments in the management of atrialfibrillation (AF), including the evolu-
tion of approaches to stroke prevention and
bleeding risk minimization, specifically
through the emergence of oral anticoagulants
(OACs).1 Vitamin K antagonists, such as
warfarin, have previously dominated theMayo Clin Proc. n May 2020;95(5):929-943 n https://doi.org/10.101
www.mayoclinicproceedings.org n ª 2019 Mayo Foundation for Me
under the CC BY-NC-ND license (http://creativecommons.org/licens
Downloaded for Anonymous User (n/a) at Aalb
For personal use only. No other uses withoutherapeutic market of AF, and nonevitamin
K oral anticoagulants (NOACs) have had
increasing presence since their approval and
inclusion in AF clinical guidelines in recent
years. Warfarin is associated with a higher
risk of major bleeding (MB) as compared
with no antithrombotic treatment.2Moreover,
required periodic monitoring of the6/j.mayocp.2019.05.032
dical Education and Research. Published by Elsevier Inc. This is an open access article
es/by-nc-nd/4.0/).
929
org Hospital from ClinicalKey.com by Elsevier on August 26, 2020.
t permission. Copyright ©2020. Elsevier Inc. All rights reserved.
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Dointernational normalized ratio (INR) and the
frequent need for dose adjustment make
warfarin inconvenient and burdensome to
the treatment of AF.3 In randomized
controlled trials comparing NOACs with
warfarin, the 4 NOACsdapixaban, dabiga-
tran, edoxaban, and rivaroxabandhave
exhibited noninferiority for safety and
efficacy.4
Concomitant comorbidities, such as dia-
betes, can complicate AF management. Dia-
betes increases the risk of developing AF and
is one of the most common comorbidities in
patients with AF.5-8 The Framingham Heart
Study reported that male and female diabetic
patients were, respectively, 4 and 6 times
more likely to developAF thandidnondiabetic
patients.9 In addition, increasing levels of he-
moglobin A1c and duration of diabetes have
been reported to increase the risk of thrombo-
embolism.10,11 Diabetes is also an independent
risk factor for stroke, anddiabeticpatientshave
more disabilities and an increased risk of mor-
tality comparedwith nondiabetic patients.12,13
Furthermore, other risk factors for stroke in
patients with AF, such as renal failure and pe-
ripheral vascular disease, aremore prevalent in
patients with diabetes.14,15 The CHA2DS2-
VASc (congestive heart failure, hypertension,
age 75 years, diabetes, stroke [previous],
vascular disease, age 65-74 years, sex) score
takes diabetes history into consideration
(contributing 1 point to the final calculation),
which emphasizes the importance of diabetes
in AF management.14 Diabetes is, therefore,
an important risk factor for diseaseprogression
and adverse outcomes in patients with AF,
making patients with diabetes a high-risk sub-
group.16-18
Because of the increased risk of stroke/
systemic embolism (SE) in patients with
diabetes, OACs are recommended for pa-
tients with AF and concomitant diabetes.19
A meta-analysis of the 4 NOAC trials found
no significant interaction between treat-
ment (NOACs vs warfarin) and diabetes
status for stroke/SE or MB.20,21 However,
in a subgroup analysis of the ARISTOTLE
(Apixaban for Reduction In Stroke and
Other Thromboembolic Events in Atrial
Fibrillation) trial, diabetes and treatmentMayo Clin Proc. n May 202
wnloaded for Anonymous User (n/a) at Aalborg Hospital from Clinica
For personal use only. No other uses without permission. Copyright ©had a significant interaction for the risk of
MB, although there is no good mechanistic
hypotheses to explain the interaction.22 In
the controlled trials, 23% to 40% of patients
had diabetes, so it is an important high-risk
subgroup study to evaluate.22-24 There have
been few observational studies comparing
NOACs and warfarin in patients with
NVAF and diabetes. To contribute real-
world evidence from several data sources
that may facilitate future research regarding
this underrepresented population, this
study analyzed the diabetes subgroup of
the ARISTOPHANES (Anticoagulants for
Reduction In Stroke: Observational Pooled
Analysis on Health Outcomes and Experi-
ence of Patients; NCT03087487) study.
The present study pooled NVAF patients
with diabetes who were newly prescribed
OACs and compared the risks of stroke/SE
and MB associated with apixaban, dabiga-
tran, rivaroxaban, and warfarin use.PATIENTS AND METHODS
Data Sources
This study was a retrospective observational
database analysis of a patient population of
more than 180 million beneficiaries per
year (w56% of the US population) using
fee-for-service Medicare data from the US
Centers for Medicare & Medicaid Services
and 4 other US commercial claims databases:
the Truven MarketScan Commercial Claims
and Encounter and Medicare Supplemental
and Coordination of Benefits Database, the
IMS PharMetrics Plus database, the Optum
Clinformatics Data Mart, and the Humana
Research database.
The databases include patients with
Medicare Fee-For-Service, Medicare Advan-
tage, and commercial insurance. Database
records include comprehensive demographic
and clinical information and International
Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes,
Healthcare Common Procedure Coding Sys-
tem codes, and National Drug Code.
Previously published articles include
detailed descriptions of the data sets, the
rationale for the pooling process, and the0;95(5):929-943 n https://doi.org/10.1016/j.mayocp.2019.05.032
www.mayoclinicproceedings.org
lKey.com by Elsevier on August 26, 2020.
2020. Elsevier Inc. All rights reserved.
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record duplicates across data sources.25,26
Patient Selection
Patients with NVAFwere selected if they had 1
or more pharmacy claim for apixaban, dabiga-
tran, rivaroxaban, or warfarin from January 1,
2013, through September 30, 2015 (identifica-
tion period). Edoxaban was evaluated but
excluded because of a small sample size due
to its recent Food and Drug Administration
approval. The first NOAC prescription date
was designated as the index date if patients
had a NOAC claim. The first warfarin prescrip-
tion date was designated as the index date for
patients without any NOAC claim. Patients
were required to have an AF diagnosis before
the index date and have continuous medical
and pharmacy health plan enrollment for 12
months ormore before the index date (baseline
period) (Supplemental Table 1, available online
at http://www.mayoclinicproceedings.org).
To evaluate new initiators, patients
treated with an OAC within 12 months
before the index date were excluded. Pa-
tients were also excluded if they had claims
indicating any of the following: valvular
heart disease (defined by the presence of In-
ternational Classification of Diseases, Ninth
Revision codes 394.xx, 396.xx, 424.0, and
745.xx), venous thromboembolism, tran-
sient AF (pericarditis, hyperthyroidism, and
thyrotoxicosis), or heart valve replacement/
transplant during the baseline period; preg-
nancy during the study period; or hip or
knee replacement surgery within 6 weeks
before the index date. Detailed selection
criteria are presented in Figure 1. Among
the resulting patients with NVAF prescribed
OACs, patients with type 1 and 2 diabetes
(ICD-9-CM code 250.xx) during the baseline
period were selected.
Outcome Measures
Outcome measures were time to first stroke/
SE, including ischemic stroke, hemorrhagic
stroke, and SE, and time to first MB,
including gastrointestinal (GI) bleeding,
intracranial hemorrhage, and bleeding at
other key sites (Supplemental Table 1).27,28
Outcomes were based on hospitalizationsMayo Clin Proc. n May 2020;95(5):929-943 n https://doi.org/10.101
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at Aalb
For personal use only. No other uses withouwith stroke/SE or MB as the principal or
first-listed diagnosis. The follow-up period
ranged from 1-day postindex date to 30
days after the discontinuation date, medica-
tion switch date, death (only inpatient death
for the commercial databases and all-cause
death for the Medicare database), end of
continuous medical or pharmacy plan
enrollment, or end of study (September 30,
2015), whichever occurred earliest.
Statistical Methods
Propensity score matching (PSM) was con-
ducted between NOAC and warfarin co-
horts (apixaban vs warfarin, dabigatran vs
warfarin, and rivaroxaban vs warfarin)
and between NOAC cohorts (apixaban vs
dabigatran, apixaban vs rivaroxaban, and
dabigatran vs rivaroxaban) within each
data set. The variables used for PSM are
related to key patient characteristics,
including demographic characteristics,
Charlson Comorbidity Index scores,29 com-
mon comorbidities, diabetes complications,
and comedications. (A complete list of
PSM model covariates is given in
Tables 1 and 2.) In each database, patients
were matched using 1:1 nearest neighbor
matching without replacement (with a
caliper of 0.01). The covariate balance
was checked using standardized differ-
ences, with a threshold of 10%.30 After
ensuring that the cohorts were balanced
in each database, study patients from the
5 data sets were pooled for the analysis.
The risk of stroke/SE and MB was evalu-
ated using Cox proportional hazards models,
with robust sandwich estimates.31 Oral anti-
coagulant treatment was included as the in-
dependent variable; as the cohorts were
balanced, no other covariates were included
in the model. P<.05 was considered statisti-
cally significant. No adjustments for multi-
ple comparisons were made.
Subgroup Analyses
Propensity score matching was conducted
again in subgroup patients on the basis of
the index dose of the NOAC. Patients pre-
scribed standard-dose (apixaban 5 mg, dabi-
gatran 150 mg, and rivaroxaban 20 mg) and6/j.mayocp.2019.05.032 931
org Hospital from ClinicalKey.com by Elsevier on August 26, 2020.
t permission. Copyright ©2020. Elsevier Inc. All rights reserved.
10,440,238 With AF diagnosis any time between
January 1, 2012, and September 30, 2015
3,537,466 With ≥1 pharmacy claim for warfarin, apixaban, dabigatran,
edoxaban, or rivaroxaban during the identification period
(from January 1, 2013, through September 30, 2015)
2,165,113 With ≥1 medical claim for AF before or on the index date
2,493,649 With ≥12 mo continuous medical and pharmacy
health plan enrollment preindex date
All patients included in the study
Matched patients 
• 13,006 Matched for
 apixaban-dabigatran
• 36,549 Matched for
 apixaban-rivaroxaban
• 13,115 Matched for
 dabigatran-rivaroxaban
167,815 With diabetes mellitus
• 12,954 Matched for
 dabigatran-warfarin
• 35,269 Matched for
 apixaban-warfarin
• 44,412 Matched for
 rivaroxaban-warfarin
895,539 With rheumatic mitral valvular heart disease, valve replacement
procedure, diagnosis of VTE, or transient AF or had cardiac surgery
in the 12 mo before or on the index were excluded
749,742 With >1 OAC treatment on the index date or had a
pharmacy claim for an OAC during the baseline period were excluded
40,328 With hip/knee replacement surgery within
6 wk before the index date were excluded
12,043 With the ICD-10 code, medical claim indicating
pregnancy during the study period, or no follow-up were excluded
• 37,558 In the apixaban cohort
• 13,128 In the dabigatran cohort
• 51,200 In the rivaroxaban cohort 
• 65,929 In the warfarin cohort
FIGURE 1. Selection criteria. Application of the selection criteria yielded more than 100,000 patients with nonvalvular atrial fibrillation
and diabetes mellitus. These patients were matched in cohorts by propensity scores. AF ¼ atrial fibrillation; ICD-10 ¼ International
Classification of Diseases, Tenth Revision; OAC ¼ oral anticoagulant; VTE ¼ venous thromboembolism.
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Dolower-dose (apixaban 2.5 mg, dabigatran 75
mg, and rivaroxaban 15 mg/10 mg) NOACs
were matched on the basis of their index
dose. Furthermore, Cox proportional haz-
ards models were completed for the
standard-dose and lower-dose subgroups
separately.Mayo Clin Proc. n May 202
wnloaded for Anonymous User (n/a) at Aalborg Hospital from Clinica
For personal use only. No other uses without permission. Copyright ©Institutional review board approval was
not required because the study did not
involve the collection, use, or transmittal of
individual identifiable data. Both the data
sets and the security of the offices in which
the analysis was completed (and in which
the data sets are kept) met the requirements0;95(5):929-943 n https://doi.org/10.1016/j.mayocp.2019.05.032
www.mayoclinicproceedings.org
lKey.com by Elsevier on August 26, 2020.
2020. Elsevier Inc. All rights reserved.
TABLE 1. Baseline Characteristics of NOACs vs Warfarin After PSMa,b
Characteristic
Apixaban
cohort
Warfarin
cohort
Dabigatran
cohort
Warfarin
cohort
Rivaroxaban
cohort
Warfarin
cohort
Sample size 35,269 35,269 12,954 12,954 44,412 44,412
Age (y) 75.89.0 75.88.9 73.79.1 73.99.3 75.28.9 75.38.9
18-54 635 (1.8) 641 (1.8) 388 (3.0) 393 (3.0) 827 (1.9) 831 (1.9)
55-64 2468 (7.0) 2447 (6.9) 1362 (10.5) 1341 (10.4) 3371 (7.6) 3362 (7.6)
65-74 12,388 (35.1) 12,306 (34.9) 5129 (39.6) 5100 (39.4) 16,542 (37.2) 16,467 (37.1)
75 19,778 (56.1) 19,875 (56.4) 6075 (46.9) 6120 (47.2) 23,672 (53.3) 23,752 (53.5)
Sex
Male 18,963 (53.8) 18,936 (53.7) 7460 (57.6) 7484 (57.8) 24,511 (55.2) 24,491 (55.1)
Female 16,306 (46.2) 16,333 (46.3) 5494 (42.4) 5470 (42.2) 19,901 (44.8) 19,921 (44.9)
US geographic region
Northeast 6402 (18.2) 6362 (18.0) 2613 (20.2) 2676 (20.7) 8488 (19.1) 8373 (18.9)
Midwest 7756 (22.0) 7869 (22.3) 2772 (21.4) 2761 (21.3) 10,653 (24.0) 10,686 (24.1)
South 15,884 (45.0) 15,863 (45.0) 5339 (41.2) 5258 (40.6) 17,883 (40.3) 17,892 (40.3)
West 5139 (14.6) 5087 (14.4) 2174 (16.8) 2209 (17.1) 7225 (16.3) 7310 (16.5)
Other 88 (0.2) 88 (0.2) 56 (0.4) 50 (0.4) 163 (0.4) 151 (0.3)
Baseline comorbidity
Deyo-Charlson Comorbidity Index score 4.72.7 4.72.8 4.12.6 4.12.6 4.52.7 4.52.7
CHA2DS2-VASc score 4.81.5 4.81.5 4.51.5 4.51.5 4.71.5 4.71.5
1 157 (0.5) 142 (0.4) 124 (1.0) 105 (0.8) 250 (0.6) 235 (0.5)
2 1515 (4.3) 1486 (4.2) 938 (7.2) 921 (7.1) 2080 (4.7) 2005 (4.5)
3 5092 (14.4) 4893 (13.9) 2430 (18.8) 2316 (17.9) 7066 (15.9) 6820 (15.4)
4 28,505 (80.8) 28,748 (81.5) 9462 (73.0) 9612 (74.2) 35,016 (78.8) 35,352 (79.6)
HAS-BLED scorec 3.51.3 3.51.3 3.21.3 3.21.3 3.41.3 3.41.3
0 134 (0.4) 159 (0.5) 101 (0.8) 120 (0.9) 229 (0.5) 253 (0.6)
1 1424 (4.0) 1490 (4.2) 855 (6.6) 837 (6.5) 2095 (4.7) 2148 (4.8)
2 6879 (19.5) 6940 (19.7) 3171 (24.5) 3132 (24.2) 9339 (21.0) 9637 (21.7)
3 26,832 (76.1) 26,680 (75.6) 8827 (68.1) 8865 (68.4) 32,749 (73.7) 32,374 (72.9)
Bleeding history 7836 (22.2) 7811 (22.1) 2517 (19.4) 2529 (19.5) 9819 (22.1) 9802 (22.1)
Congestive heart failure 13,516 (38.3) 13,603 (38.6) 4197 (32.4) 4275 (33.0) 16,320 (36.7) 16,352 (36.8)
Type 1 diabetesd 5146 (14.6) 5322 (15.1) 1920 (14.8) 1786 (13.8) 6474 (14.6) 6477 (14.6)
Type 2 diabetesd 35,019 (99.3) 35,048 (99.4) 12,873 (99.4) 12,871 (99.4) 44,064 (99.2) 44,132 (99.4)
Hypertension 33,642 (95.4) 33,652 (95.4) 12,220 (94.3) 12,237 (94.5) 41,984 (94.5) 41,986 (94.5)
Renal disease 12,557 (35.6) 12,639 (35.8) 3337 (25.8) 3365 (26.0) 13,869 (31.2) 13,726 (30.9)
Liver disease 2234 (6.3) 2205 (6.3) 753 (5.8) 788 (6.1) 2888 (6.5) 2814 (6.3)
Myocrdial infarction 4372 (12.4) 4385 (12.4) 1276 (9.9) 1294 (10.0) 5365 (12.1) 5395 (12.1)
Dyspepsia or stomach discomfort 8238 (23.4) 8287 (23.5) 2654 (20.5) 2593 (20.0) 10,187 (22.9) 10,042 (22.6)
Nonstroke/ SE peripheral vascular disease 22,511 (63.8) 22,479 (63.7) 7574 (58.5) 7553 (58.3) 27,328 (61.5) 27,382 (61.7)
Stroke/SE 5110 (14.5) 5036 (14.3) 1608 (12.4) 1657 (12.8) 6124 (13.8) 6190 (13.9)
Transient ischemic attack 2816 (8.0) 2861 (8.1) 891 (6.9) 897 (6.9) 3350 (7.5) 3365 (7.6)
Anemia and coagulation defects 12,969 (36.8) 12,928 (36.7) 3893 (30.1) 3960 (30.6) 15,663 (35.3) 15,534 (35.0)
Alcoholism 612 (1.7) 605 (1.7) 265 (2.0) 250 (1.9) 918 (2.1) 922 (2.1)
Peripheral artery disease 9366 (26.6) 9687 (27.5) 2943 (22.7) 3089 (23.8) 11,557 (26.0) 11,599 (26.1)
Coronary artery disease 20,088 (57.0) 19,903 (56.4) 6709 (51.8) 6630 (51.2) 24,174 (54.4) 24,144 (54.4)
Obesity 10,725 (30.4) 10,692 (30.3) 3779 (29.2) 3750 (28.9) 13,041 (29.4) 13,002 (29.3)
Hypoglycemia 909 (2.6) 990 (2.8) 312 (2.4) 283 (2.2) 1178 (2.7) 1156 (2.6)
Dyslipidemia 30,820 (87.4) 30,793 (87.3) 11,132 (85.9) 11,132 (85.9) 38,222 (86.1) 38,099 (85.8)
Diabetic nephropathy 4004 (11.4) 4032 (11.4) 1073 (8.3) 1079 (8.3) 4221 (9.5) 4140 (9.3)
Diabetic neuropathy 7375 (20.9) 7348 (20.8) 2438 (18.8) 2439 (18.8) 8759 (19.7) 8892 (20.0)
Diabetic retinopathy 4262 (12.1) 4278 (12.1) 1458 (11.3) 1510 (11.7) 5022 (11.3) 5072 (11.4)
Continued on next page
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TABLE 1. Continued
Characteristic
Apixaban
cohort
Warfarin
cohort
Dabigatran
cohort
Warfarin
cohort
Rivaroxaban
cohort
Warfarin
cohort
Baseline medication use
ACEi/ARB 25,712 (72.9) 25,790 (73.1) 9519 (73.5) 9533 (73.6) 32,172 (72.4) 32,362 (72.9)
Amiodarone 4548 (12.9) 4542 (12.9) 1523 (11.8) 1535 (11.8) 5350 (12.0) 5424 (12.2)
b-blockers 21,646 (61.4) 21,569 (61.2) 7751 (59.8) 7744 (59.8) 27,087 (61.0) 27,059 (60.9)
H2-receptor antagonists 2889 (8.2) 2881 (8.2) 956 (7.4) 925 (7.1) 3598 (8.1) 3585 (8.1)
Proton pump inhibitors 12,554 (35.6) 12,621 (35.8) 4195 (32.4) 4203 (32.4) 15,252 (34.3) 15,229 (34.3)
Statins 25,459 (72.2) 25,409 (72.0) 8966 (69.2) 8978 (69.3) 31,263 (70.4) 31,310 (70.5)
Anti-platelets 9206 (26.1) 9132 (25.9) 2860 (22.1) 2852 (22.0) 10,741 (24.2) 10,692 (24.1)
NSAIDS 8940 (25.3) 8888 (25.2) 3445 (26.6) 3456 (26.7) 11,210 (25.2) 11,158 (25.1)
Diuretics 22,484 (63.8) 22,506 (63.8) 7972 (61.5) 8002 (61.8) 27,610 (62.2) 27,674 (62.3)
Calcium channel blockers 16,540 (46.9) 16,584 (47.0) 5921 (45.7) 5932 (45.8) 20,465 (46.1) 20,501 (46.2)
Baseline diabetes medications
Biguanides 14,764 (41.9) 14,818 (42.0) 6000 (46.3) 6027 (46.5) 18,927 (42.6) 19,071 (42.9)
Sulphonylureas 9199 (26.1) 9269 (26.3) 3513 (27.1) 3602 (27.8) 11,702 (26.3) 11,789 (26.5)
Meglitinide 405 (1.1) 396 (1.1) 147 (1.1) 141 (1.1) 529 (1.2) 520 (1.2)
Thiazolidinediones 1540 (4.4) 1583 (4.5) 641 (4.9) 608 (4.7) 1934 (4.4) 1930 (4.3)
DPP-4 inhibitors 3875 (11.0) 3892 (11.0) 1461 (11.3) 1474 (11.4) 4664 (10.5) 4600 (10.4)
Insulin 8199 (23.2) 8180 (23.2) 2886 (22.3) 2855 (22.0) 10,109 (22.8) 10,211 (23.0)
a-glucosidase inhibitors 166 (0.5) 156 (0.4) 58 (0.4) 64 (0.5) 195 (0.4) 178 (0.4)
SGLT-2 inhibitors 170 (0.5) 165 (0.5) 67 (0.5) 62 (0.5) 180 (0.4) 182 (0.4)
GLP-1 agonists 788 (2.2) 797 (2.3) 320 (2.5) 299 (2.3) 896 (2.0) 899 (2.0)
Dose of the index prescription
Standard dosee 26,383 (74.8) 10,493 (81.0) 30,215 (68.0)
Lower dosef 8886 (25.2) 2461 (19.0) 14,197 (32.0)
Follow-up time (d)
Mean 183.3166.7 240.5218.0 224.5223.5 244.6220.8 225.4213.7 244.0220.0
Median 121 158 122 161 142 162
aACEi/ARB ¼ angiotensin converting enzyme inhibitors/angiotensin-receptor blocker; CHA2DS2-VASc ¼ congestive heart failure, hypertension, aged 75 years, diabetes
mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65-74 years, sex category; DPP-4 ¼ dipeptidyl peptidase 4; GLP-1 ¼ glucagon-
like peptide; HAS-BLED ¼ hypertension, abnormal (renal/liver function), stroke, bleeding, labile (international normalized ratio), elderly, drug/alcohol/medication (usage
history); NOAC ¼ non-vitamin K oral anticoagulant; NSAIDs ¼ non-steroidal anti-inflammatory drugs; PSM ¼ propensity score matching; SE ¼ systemic embolism; SGLT-2
¼ sodium-glucose co-transporter 2.
bData are presented as mean  SD or as No. (percentage).
cAs the international normalized ratio value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8.
dDiabetes type was defined by the presence of International Classification of Disease, Ninth Revision, Clinical Modification diagnosis codes only and was not further validated.
eStandard dose: 5mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban.
fLower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; 2,460 patients treated with rivaroxaban were prescribed 10 mg rivaroxaban.
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Doof the Health Insurance Portability and
Accountability Act of 1996.
RESULTS
After applying the selection criteria, a total of
167,815 patients with NVAF and concomitant
diabetes mellitus (35.9% of patients with
NVAF [466,991]) were identified, including
37,558 patients prescribed apixaban, 13,128
dabigatran, 51,200 rivaroxaban, and 65,929
warfarin (Figure 1). Before PSM, patientsMayo Clin Proc. n May 202
wnloaded for Anonymous User (n/a) at Aalborg Hospital from Clinica
For personal use only. No other uses without permission. Copyright ©prescribed warfarin were the oldest and had
the highest CHA2DS2-VASc and hyperten-
sion, abnormal (renal/liver function), stroke,
bleeding, labile (international normalized ra-
tio), elderly, drug/alcohol/medication (usage
history) (HAS-BLED) scores, followed by
those prescribed apixaban, rivaroxaban, and
dabigatran. The number of patients who
were prescribed the lower dose in each cohort
was 9180 (24%) of those prescribed apixaban
(2.5 mg), 2467 (19%) of those prescribed0;95(5):929-943 n https://doi.org/10.1016/j.mayocp.2019.05.032
www.mayoclinicproceedings.org
lKey.com by Elsevier on August 26, 2020.
2020. Elsevier Inc. All rights reserved.
TABLE 2. Baseline Characteristics of NOACs vs NOACs After PSMa,b
Characteristic
Apixaban
cohort
Dabigatran
cohort
Apixaban
cohort
Rivaroxaban
cohort
Dabigatran
cohort
Rivaroxaban
cohort
Sample size 13,006 13,006 36,549 36,549 13,115 13,115
Age (y) 73.89.4 73.69.2 75.39.3 75.29.2 73.59.2 73.59.4
18-54 426 (3.3) 430 (3.3) 881 (2.4) 869 (2.4) 444 (3.4) 441 (3.4)
55-64 1373 (10.6) 1402 (10.8) 3014 (8.2) 2995 (8.2) 1432 (10.9) 1421 (10.8)
65-74 5100 (39.2) 5107 (39.3) 12,866 (35.2) 12,860 (35.2) 5160 (39.3) 5175 (39.5)
75 6107 (47.0) 6067 (46.6) 19,788 (54.1) 19,825 (54.2) 6079 (46.4) 6078 (46.3)
Sex
Male 7526 (57.9) 7499 (57.7) 19,761 (54.1) 19,688 (53.9) 7596 (57.9) 7656 (58.4)
Female 5480 (42.1) 5507 (42.3) 16,788 (45.9) 16,861 (46.1) 5519 (42.1) 5459 (41.6)
US geographic region
Northeast 2560 (19.7) 2604 (20.0) 6423 (17.6) 6427 (17.6) 2645 (20.2) 2674 (20.4)
Midwest 2758 (21.2) 2766 (21.3) 7737 (21.2) 7682 (21.0) 2779 (21.2) 2750 (21.0)
South 5496 (42.3) 5441 (41.8) 17,130 (46.9) 17,200 (47.1) 5450 (41.6) 5503 (42.0)
West 2142 (16.5) 2142 (16.5) 5174 (14.2) 5160 (14.1) 2181 (16.6) 2133 (16.3)
Other 50 (0.4) 53 (0.4) 85 (0.2) 80 (0.2) 60 (0.5) 55 (0.4)
Baseline comorbidity
Deyo-Charlson Comorbidity Index score 4.12.6 4.12.6 4.52.7 4.52.7 4.12.6 4.12.6
CHA2DS2-VASc score 4.51.5 4.41.5 4.71.5 4.71.5 4.41.5 4.41.5
1 104 (0.8) 121 (0.9) 192 (0.5) 193 (0.5) 130 (1.0) 127 (1.0)
2 967 (7.4) 1007 (7.7) 1941 (5.3) 1950 (5.3) 1040 (7.9) 1072 (8.2)
3 2445 (18.8) 2432 (18.7) 5588 (15.3) 5515 (15.1) 2470 (18.8) 2383 (18.2)
4 9490 (73.0) 9446 (72.6) 28,828 (78.9) 28,891 (79.0) 9475 (72.2) 9533 (72.7)
HAS-BLED scorec 3.21.3 3.21.3 3.41.3 3.41.3 3.21.3 3.21.3
0 89 (0.7) 102 (0.8) 167 (0.5) 157 (0.4) 106 (0.8) 110 (0.8)
1 849 (6.5) 890 (6.8) 1722 (4.7) 1786 (4.9) 916 (7.0) 892 (6.8)
2 3131 (24.1) 3191 (24.5) 7428 (20.3) 7301 (20.0) 3229 (24.6) 3176 (24.2)
3 8937 (68.7) 8823 (67.8) 27,232 (74.5) 27,305 (74.7) 8864 (67.6) 8937 (68.1)
Bleeding history 2529 (19.4) 2508 (19.3) 7798 (21.3) 7869 (21.5) 2521 (19.2) 2544 (19.4)
Congestive heart failure 4229 (32.5) 4182 (32.2) 13,362 (36.6) 13,373 (36.6) 4202 (32.0) 4308 (32.8)
Type 1 diabetesd 1802 (13.9) 1926 (14.8) 5151 (14.1) 5397 (14.8) 1938 (14.8) 1874 (14.3)
Type 2 diabetesd 12,903 (99.2) 12,924 (99.4) 36,295 (99.3) 36,290 (99.3) 13,030 (99.4) 13,006 (99.2)
Hypertension 12,288 (94.5) 12,282 (94.4) 34,855 (95.4) 34,837 (95.3) 12,374 (94.3) 12,385 (94.4)
Renal disease 3336 (25.6) 3331 (25.6) 12,030 (32.9) 12,108 (33.1) 3338 (25.5) 3314 (25.3)
Liver disease 766 (5.9) 754 (5.8) 2337 (6.4) 2358 (6.5) 758 (5.8) 732 (5.6)
Myocardial infarction 1297 (10.0) 1274 (9.8) 4332 (11.9) 4330 (11.8) 1277 (9.7) 1288 (9.8)
Dyspepsia or stomach discomfort 2665 (20.5) 2650 (20.4) 8479 (23.2) 8570 (23.4) 2666 (20.3) 2693 (20.5)
Nonstroke/SE peripheral vascular disease 7548 (58.0) 7572 (58.2) 22,962 (62.8) 23,016 (63.0) 7619 (58.1) 7543 (57.5)
Stroke/SE 1642 (12.6) 1607 (12.4) 5046 (13.8) 5069 (13.9) 1606 (12.2) 1628 (12.4)
Transient ischemic attack 875 (6.7) 895 (6.9) 2866 (7.8) 2903 (7.9) 894 (6.8) 893 (6.8)
Anemia and coagulation defects 3864 (29.7) 3876 (29.8) 12,768 (34.9) 12,830 (35.1) 3894 (29.7) 3890 (29.7)
Alcoholism 287 (2.2) 261 (2.0) 638 (1.7) 652 (1.8) 269 (2.1) 278 (2.1)
Peripheral artery disease 2979 (22.9) 2938 (22.6) 9342 (25.6) 9780 (26.8) 2952 (22.5) 3002 (22.9)
Coronary artery disease 6672 (51.3) 6711 (51.6) 20,503 (56.1) 20,347 (55.7) 6754 (51.5) 6632 (50.6)
Obesity 3849 (29.6) 3827 (29.4) 11,272 (30.8) 11,355 (31.1) 3835 (29.2) 3821 (29.1)
Hypoglycemia 295 (2.3) 310 (2.4) 912 (2.5) 976 (2.7) 313 (2.4) 304 (2.3)
Dyslipidemia 11,157 (85.8) 11,183 (86.0) 32,023 (87.6) 32,092 (87.8) 11,268 (85.9) 11,286 (86.1)
Diabetic nephropathy 1089 (8.4) 1073 (8.3) 3685 (10.1) 3681 (10.1) 1076 (8.2) 1023 (7.8)
Diabetic neuropathy 2479 (19.1) 2440 (18.8) 7357 (20.1) 7340 (20.1) 2455 (18.7) 2466 (18.8)
Diabetic retinopathy 1486 (11.4) 1459 (11.2) 4248 (11.6) 4297 (11.8) 1474 (11.2) 1472 (11.2)
Continued on next page
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TABLE 2. Continued
Characteristic
Apixaban
cohort
Dabigatran
cohort
Apixaban
cohort
Rivaroxaban
cohort
Dabigatran
cohort
Rivaroxaban
cohort
Baseline medication use
ACEi/ARB 9571 (73.6) 9576 (73.6) 26,897 (73.6) 26,855 (73.5) 9656 (73.6) 9669 (73.7)
Amiodarone 1498 (11.5) 1528 (11.7) 4679 (12.8) 4710 (12.9) 1536 (11.7) 1580 (12.0)
b-blockers 7743 (59.5) 7792 (59.9) 22,538 (61.7) 22,578 (61.8) 7842 (59.8) 7772 (59.3)
H2-receptor antagonists 954 (7.3) 949 (7.3) 2935 (8.0) 2974 (8.1) 956 (7.3) 1008 (7.7)
Proton pump inhibitors 4332 (33.3) 4219 (32.4) 13,034 (35.7) 13,084 (35.8) 4231 (32.3) 4309 (32.9)
Statins 9035 (69.5) 8995 (69.2) 26,354 (72.1) 26,379 (72.2) 9057 (69.1) 9023 (68.8)
Anti-platelets 2868 (22.1) 2864 (22.0) 9514 (26.0) 9587 (26.2) 2878 (21.9) 2921 (22.3)
NSAIDs 3557 (27.3) 3499 (26.9) 9731 (26.6) 9714 (26.6) 3533 (26.9) 3527 (26.9)
Diuretics 8041 (61.8) 7998 (61.5) 23,044 (63.0) 23,067 (63.1) 8057 (61.4) 8095 (61.7)
Calcium channel blockers 5988 (46.0) 5966 (45.9) 17,188 (47.0) 17,183 (47.0) 6006 (45.8) 5962 (45.5)
Baseline diabetes medications
Biguanides 6091 (46.8) 6066 (46.6) 15,989 (43.7) 15,921 (43.6) 6130 (46.7) 6089 (46.4)
Sulphonylureas 3565 (27.4) 3505 (26.9) 9416 (25.8) 9378 (25.7) 3550 (27.1) 3574 (27.3)
Meglitinide 157 (1.2) 151 (1.2) 427 (1.2) 438 (1.2) 151 (1.2) 150 (1.1)
Thiazolidinediones 674 (5.2) 672 (5.2) 1702 (4.7) 1689 (4.6) 681 (5.2) 708 (5.4)
DPP-4 inhibitors 1537 (11.8) 1503 (11.6) 4321 (11.8) 4282 (11.7) 1519 (11.6) 1559 (11.9)
Insulin 2875 (22.1) 2890 (22.2) 8252 (22.6) 8244 (22.6) 2919 (22.3) 2949 (22.5)
a-glucosidase inhibitors 56 (0.4) 57 (0.4) 168 (0.5) 168 (0.5) 56 (0.4) 60 (0.5)
SGLT-2 inhibitors 72 (0.6) 78 (0.6) 364 (1.0) 357 (1.0) 81 (0.6) 83 (0.6)
GLP-1 agonists 402 (3.1) 355 (2.7) 1016 (2.8) 1001 (2.7) 356 (2.7) 357 (2.7)
Dose of the index prescription
Standard dosee 10,545 (81.1) 10,543 (81.1) 27,852 (76.2) 24,605 (67.3) 10,648 (81.2) 9509 (72.5)
Lower dosef 2461 (18.9) 2463 (18.9) 8697 (23.8) 11,944 (32.7) 2467 (18.8) 3606 (27.5)
Follow-up time (d)
Mean 187.6171.0 225.0223.5 183.7167.0 225.5213.7 224.6223.3 230.0216.9
Median 124 123 122 142 123 147
aACEi/ARB ¼ angiotensin converting enzyme inhibitors/angiotensin-receptor blocker; CHA2DS2-VASc ¼ congestive heart failure, hypertension, aged 75 years, diabetes
mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65-74 years, sex category; DPP-4 ¼ dipeptidyl peptidase 4; GLP-1 ¼ glucagon-
like peptide; HAS-BLED ¼ hypertension, abnormal (renal/liver function), stroke, bleeding, labile (international normalized ratio), elderly, drug/alcohol/medication (usage
history); NOAC ¼ non-vitamin K oral anticoagulant; NSAIDs ¼ non-steroidal anti-inflammatory drugs; PSM ¼ propensity score matching; SE ¼ systemic embolism; SGLT-2
¼ sodium-glucose co-transporter 2.
bData are presented as mean  SD or as No. (percentage).
cAs the international normalized ratio value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8.
dDiabetes type was defined by the presence of International Classification of Disease, Ninth Revision, Clinical Modification diagnosis codes only and was not further validated.
eStandard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban.
fLower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; 2,005 and 672 patients were prescribed 10 mg of rivaroxaban in the apixaban-rivaroxaban and
dabigatran-rivaroxaban cohorts, respectively.
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Dodabigatran (75 mg), and 12,477 (24%) of
those prescribed rivaroxaban (15 mg). In
addition, 5% of patients treated with rivarox-
aban were prescribed 10 mg of rivaroxaban
(Supplemental Table 2, available online at
http://www.mayoclinicproceedings.org).
The unadjusted incidence rates of stroke/
SE in the warfarin, apixaban, dabigatran, and
rivaroxaban cohorts were 2.5, 1.7, 1.8, and
1.7 events per 100 person-years, respec-
tively. The unadjusted incidence rates ofMayo Clin Proc. n May 202
wnloaded for Anonymous User (n/a) at Aalborg Hospital from Clinica
For personal use only. No other uses without permission. Copyright ©MB in the warfarin, apixaban, dabigatran,
and rivaroxaban cohorts were 8.2, 4.8, 4.8,
and 6.9 events per 100 person-years, respec-
tively (Supplemental Table 3, available on-
line at http://www.mayoclinicproceedings.
org).
After PSM, a total of 154,324 unique pa-
tients were included. PSM produced 35,269,
12,954, and 44,412 patient pairs for the
apixaban-warfarin, dabigatran-warfarin, and
rivaroxaban-warfarin cohorts, respectively.0;95(5):929-943 n https://doi.org/10.1016/j.mayocp.2019.05.032
www.mayoclinicproceedings.org
lKey.com by Elsevier on August 26, 2020.
2020. Elsevier Inc. All rights reserved.
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13,006, 36,549, and 13,115 patient pairs for
the apixaban-dabigatran, apixaban-rivaroxa-
ban, and dabigatran-rivaroxaban cohorts,
respectively (Figure 1). The baseline charac-
teristics of the matched populations are listed
in Tables 1 and 2. After matching, all demo-
graphic and clinical characteristics were
well balanced. Across the matched cohorts
during the baseline period, 22% to 23%,
42% to 47%, and 26% to 28% were prescribed
insulin, biguanides, and sulfonylureas,
respectively. The mean follow-up ranged be-
tween 6 and 8 months in all matched cohorts.
The baseline characteristics of patients
with NVAF prescribed standard- and lower-
dosed NOACs are summarized in
Supplemental Tables 4, 5, 6, and 7 (available
online at http://www.mayoclinicproceedings.
org).
NoneVitamin K Oral Anticoagulant and
Warfarin Comparisons
Compared with warfarin, apixaban (hazard
ratio [HR], 0.67; 95%CI, 0.57-0.77) and rivar-
oxaban (HR, 0.79; 95% CI, 0.71-0.89) were
associated with a lower risk of stroke/SE.
There was no significant difference in the
risk of stroke/SE (HR, 0.84; 95% CI, 0.67-
1.07) between dabigatran and warfarin.
Compared with those prescribed warfarin, pa-
tients prescribed apixaban had a 26% lower
risk of ischemic stroke (HR, 0.74; 95%
CI, 0.65-0.85) whereas those prescribed rivar-
oxaban had a 14% lower risk of ischemic
stroke (HR, 0.86; 95% CI, 0.77-0.97)
(Figure 2A). In addition, patients prescribed
apixaban (HR, 0.48; 95% CI, 0.30-0.77), dabi-
gatran (HR, 0.36; 95% CI, 0.21-0.60) and
rivaroxaban (HR, 0.56; 95% CI, 0.45-0.69)
had a lower risk of hemorrhagic stroke than
did patients prescribed warfarin.
Compared with warfarin, apixaban (HR,
0.60; 95% CI, 0.56-0.65) and dabigatran (HR,
0.78; 95% CI, 0.69-0.88) were associated with
a lower risk of MB. Compared with warfarin,
rivaroxaban was associated with a similar risk
of MB (HR, 1.02; 95% CI, 0.94-1.10).
Compared with those prescribed
warfarin, patients prescribed apixaban had
a lower risk of GI bleeding (HR, 0.58; 95%Mayo Clin Proc. n May 2020;95(5):929-943 n https://doi.org/10.101
www.mayoclinicproceedings.org
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For personal use only. No other uses withouCI, 0.53-0.65), patients prescribed rivaroxa-
ban had a higher risk of GI bleeding
(HR, 1.19; 95% CI, 1.09-1.30), and patients
prescribed dabigatran had a similar risk of
GI bleeding (HR, 0.99; 95% CI, 0.84-1.17).
All NOACs were associated with a lower
risk of intracranial hemorrhage compared
with warfarin (Figure 2A).
NoneVitamin K Oral Anticoagulant and
NOAC Comparisons
Apixaban was associated with a lower risk of
stroke/SE compared with dabigatran (HR,
0.78; 95% CI, 0.64-0.94) and rivaroxaban
(HR, 0.87; 95% CI, 0.75-1.00). Similarly,
apixaban was associated with a lower risk
of MB compared with dabigatran (HR,
0.73; 95% CI, 0.63-0.84) and rivaroxaban
(HR, 0.59; 95% CI, 0.54-0.65), both driven
by GI bleeding. Dabigatran was associated
with a similar risk of stroke/SE (HR, 1.11;
95%, 0.85-1.46) and lower risk of MB (HR,
0.76; 95% CI, 0.66-0.86) compared with
rivaroxaban (Figure 2B).
The Kaplan-Meier curves for the cumula-
tive incidence rates of stroke/SE and MB in
the matched populations are shown in
Supplemental Figure 1A and B (available on-
line at http://www.mayoclinicproceedings.
org).
The results of the standard- and low-dose
subgroup analysis were generally consistent
with the main analysis (Figure 3).
DISCUSSION
This ARISTOPHANES analysis of a high-risk
subgroup of diabetic patients is the largest
retrospective observational study to date
that examines the risk of stroke/SE and MB
patients with NVAF and diabetes who have
initiated OAC treatment. The relevance of
evaluating diabetic patients as a high-risk
subgroup is paramount, as diabetes is one of
the most common concomitant comorbid
conditions in patients with AF.6,7 With
pooled data of US Centers for Medicare &
Medicaid Services Medicare and 4 large US
national claims databases, this study found
that apixaban and rivaroxaban were associ-
ated with lower rates of stroke/SE compared
with warfarin. In addition, apixaban and6/j.mayocp.2019.05.032 937
org Hospital from ClinicalKey.com by Elsevier on August 26, 2020.
t permission. Copyright ©2020. Elsevier Inc. All rights reserved.
Comparator Reference Hazard ratio
(95% CI)Incidence rate (per 100 person-years)
Apixaban vs Warfarin (ref.) N=35,269 N=35,269
Stroke/SE 1.7 2.4 0.67 (0.57-0.77) <.001
Ischemic 1.4 1.7 0.74 (0.65-0.85) <.001
Hemorrhagic 0.3 0.7 0.48 (0.30-0.77) .002
Major bleeding 5.0 7.5 0.60 (0.56-0.65) <.001
GI bleeding 2.4 3.7 0.58 (0.53-0.65) <.001
ICH 0.7 1.1 0.59 (0.46-0.75) <.001
Dabigatran vs Warfarin (ref.) N=12,954 N=12,954
Stroke/SE 1.9 2.2 0.84 (0.67-1.07) .16
Ischemic 1.6 1.5 1.00 (0.81-1.25) .97
Hemorrhagic 0.2 0.6 0.36 (0.21-0.60) <.001
Major bleeding 4.8 6.1 0.78 (0.69-0.88) <.001
GI bleeding 2.9 2.9 0.99 (0.84-1.17) .93
ICH 0.5 1.0 0.48 (0.35-0.66) <.001
Rivaroxaban vs Warfarin (ref.) N=44,412 N=44,412
Stroke/SE 1.9 2.3 0.79 (0.71-0.89) <.001
Ischemic 1.4 1.6 0.86 (0.77-0.97) .01
Hemorrhagic 0.3 0.6 0.56 (0.45-0.69) <.001
Major bleeding 7.3 7.1 1.02 (0.94-1.10) .67
GI bleeding 4.1 3.4 1.19 (1.09-1.30) <.001
ICH 0.6 1.1 0.56 (0.46-0.68) <.001
-valueP
A
Favors NOACs
0.20 0.40 0.60 0.80 1.00 1.20 1.40
Favors Warfarin
FIGURE 2. Incidence and hazard ratios of (A) NOACs vs warfarin and (B) NOACs vs NOACs. Incidence rates were measured per
100 person-years for matched NOAC cohorts. Hazard ratios were measured along with 95% CIs. aUpper limit of 95% was rounded
from 0.997 to 1.00. GI ¼ gastrointestinal; ICH ¼ intracranial hemorrhage; NOAC ¼ nonevitamin K oral anticoagulant; ref. ¼
reference; SE ¼ systemic embolism.
MAYO CLINIC PROCEEDINGS
938
Dodabigatran were associated with lower rates of
MB compared with warfarin. As a hypothesis-
generating analysis, NOAC and NOAC com-
parisons suggested that there was a signifi-
cantly lower risk of stroke/SE with apixaban
compared to dabigatran and rivaroxaban.
Apixaban was associated with a lower risk
of MB compared with dabigatran and rivarox-
aban and dabigatran was associated with a
lower risk of MB compared with rivaroxaban.
Subgroup analyses of the ARISTOTLE,
Randomized Evaluation of Long-term Anti-
coagulation Therapy (RE-LY) and Rivaroxa-
ban Once-daily Oral Direct Factor Xa
Inhibition Compared with Vitamin KMayo Clin Proc. n May 202
wnloaded for Anonymous User (n/a) at Aalborg Hospital from Clinica
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bolism Trial in Atrial Fibrillation (ROCKET-
AF) trials have revealed that apixaban, dabi-
gatran, and rivaroxaban have no significant
interaction with diabetes status for the reduc-
tion of stroke/SE.22-24 However, in the dia-
betes subgroup analysis of the ARISTOTLE
trial, apixaban was associated with a reduc-
tion in MB in patients without diabetes (HR,
0.60; 95% CI, 0.51-0.72) but a similar risk
of MB in patients with diabetes (HR, 0.96;
95% CI, 0.74-1.25; Pinteraction¼.003)
compared with warfarin.22 The significant
interaction may have been due to chance.
There was no significant interaction for0;95(5):929-943 n https://doi.org/10.1016/j.mayocp.2019.05.032
www.mayoclinicproceedings.org
lKey.com by Elsevier on August 26, 2020.
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Comparator Reference Hazard ratio
(95% CI)Incidence rate (per 100 person-years)
N=13,006 N=13,006
Stroke/SE 1.5 1.9
Ischemic 1.3 1.6
Hemorrhagic 0.3 0.2
Major bleeding 3.8 4.8
GI bleeding 1.9 3.0
ICH 0.6 0.5
N=36,549 N=36,549
Stroke/SE 1.7 1.8
Ischemic 1.3 1.4
Hemorrhagic 0.3 0.4
Major bleeding 4.8 7.4
GI bleeding 2.3 4.2
ICH 0.7 0.6
N=13,115 N=13,115
Stroke/SE
Ischemic
Hemorrhagic
Major bleeding
GI bleeding
ICH
B Favors comparator
1.00 1.20 1.400.800.600.400.20
Favors reference
-valueP
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FIGURE 2. (continued).
SAFETY AND EFFECTIVENESS OF ORAL ANTICOAGULANTSintracranial hemorrhage; apixaban was asso-
ciated with reduced intracranial hemorrhage
compared with warfarin in patients with
and without diabetes. The ROCKET-AF and
the RE-LY trials reported that the incidence
of MB for dabigatran (150 mg) or rivaroxaban
was similar to that for warfarin, regardless of
diabetes status.23,24 Meta-analyses of ran-
domized controlled trials (including ARIS-
TOTLE, RE-LY, ROCKET-AF, and Effective
Anticoagulation with Factor Xa Next Genera-
tion in Atrial Fibrillation [ENGAGE-AF])
have revealed that diabetes status has no dif-
ferential effect on the safety or effectiveness of
all NOACs combined vs warfarin.
Nonevitamin K oral anticoagulants were
found to reduce the risk of stroke/SE and
MB compared with warfarin in both diabetic
and nondiabetic patients.20,21Mayo Clin Proc. n May 2020;95(5):929-943 n https://doi.org/10.101
www.mayoclinicproceedings.org
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have evaluated clinical outcomes in patients
with NVAF and diabetes prescribed NOACs.
One retrospective study using US commer-
cial claims, leveraging data from the Truven
MarketScan database, found no significant
difference in the risk of stroke/SE and MB
between rivaroxaban and warfarin therapy
in diabetic patients with NVAF.32 A study
of US Department of Defense records found
that rivaroxaban was associated with a
higher incidence of MB in diabetic patients
than in nondiabetic patients (3.7 events per
100 person-years vs 2.5 events per 100 per-
son-years).33 A study in Taiwan in diabetic
patients with NVAF found that compared
with those prescribed warfarin, patients pre-
scribed dabigatran had a lower risk of all-
cause mortality and GI bleeding whereas6/j.mayocp.2019.05.032 939
org Hospital from ClinicalKey.com by Elsevier on August 26, 2020.
t permission. Copyright ©2020. Elsevier Inc. All rights reserved.
Standard dose Lower dose
Incidence
(per 100 person-years)
Incidence
(per 100 person-years)Hazard ratio (95% CI) -value Hazard ratio (95% CI)
Apixaban (com.) vs Warfarin (ref.)
Stroke/SE 1.5 vs 2.1 0.66 (0.56-0.78) <.001 2.4 vs 3.5 0.64 (0.50-0.83) <.001
Major bleeding 4.6 vs 6.5 0.65 (0.60-0.71) <.001 6.0 vs 10.4 0.54 (0.47-0.61) <.001
Dabigatran (com.) vs Warfarin (ref.)
Stroke/SE 1.6 vs 1.7 0.97 (0.70-1.34) .83 2.8 vs 3.1 0.89 (0.61-1.29) .52
Major bleeding 4.2 vs 5.5 0.75 (0.65-0.87) <.001 7.5 vs 10.7 0.70 (0.55-0.89) .004
Rivaroxaban (com.) vs Warfarin (ref.)
Stroke/SE 1.6 vs 2.0 0.81 (0.71-0.92) .001 2.3 vs 3.0 0.75 (0.64-0.88) <.001
Major bleeding 6.4 vs 5.9 1.07 (0.97-1.19) .19 9.4 vs 9.2 0.99 (0.90-1.08) .77
Apixaban (com.) vs Dabigatran (ref.)
Stroke/SE 1.3 vs 1.6 0.76 (0.61-0.95) 0.02 2.3 vs 2.8 0.74 (0.49-1.11) .15
Major bleeding 3.9 vs 4.2 0.87 (0.73-1.03) .11 5.0 vs 7.6 0.58 (0.42-0.79) .001
Apixaban (com.) vs Rivaroxaban (ref.)
Stroke/SE 1.4 vs 1.6 0.84 (0.70-1.00)a .049 2.4 vs 2.5 0.87 (0.68-1.13) .29
Major bleeding 4.2 vs 6.5 0.59 (0.54-0.65) <.001 6.0 vs 10.4 0.55 (0.48-0.63) <.001
Dabigatran (com.) vs Rivaroxaban (ref.)
Stroke/SE 1.6 vs 1.4 1.16 (0.86-1.58) .33 2.8 vs 1.7 1.65 (1.01-2.68) .045
Major bleeding 4.2 vs 5.9 0.72 (0.60-0.85) <.001 7.6 vs 9.6 0.82 (0.65-1.03) .09
0.2 0.6 1 1.4 1.8
Favors comparator Favors reference
0.2 0.6 1 1.4 1.8
Favors comparator Favors reference
P -valueP
FIGURE 3. Incidence and hazard ratios for dose subgroup analysis. Incidence rates were measured per 100 person-years for matched
nonevitamin K oral anticoagulant cohorts. Hazard ratios were measured along with 95% CIs. comp. ¼ comparator; ref. ¼ reference;
SE ¼ systemic embolism. aUpper limit of 95% was rounded from 0.999 to 1.00.
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Dothose prescribed rivaroxaban had a similar
risk of mortality, stroke, and bleeding.
Also, compared with those prescribed rivar-
oxaban, patients prescribed dabigatran had
significantly lower rates of all-cause mortal-
ity.34 An analysis of patients with and
without diabetes from a retrospective obser-
vational study, leveraging data from US
HealthCore claims, revealed that patients
prescribed rivaroxaban had MB event rates
similar to those of patients prescribed
warfarin; however, compared with those pre-
scribed warfarin, patients prescribed apixa-
ban and dabigatran were associated with a
reduction in MB events, regardless of dia-
betes status.35 Both patients prescribed dabi-
gatran and those prescribed apixaban had a
lower risk of MB than did those prescribed
rivaroxaban among patients with and
without diabetes. Compared with those pre-
scribed dabigatran, patients prescribed apix-
aban had a similar risk of MB irrespective of
diabetes status.35
Compared with previous studies, the
ARISTOPHANES study included a larger
sample of patients with NVAF and concom-
itant diabetes, providing this analysis with
higher statistical power. Consistent withMayo Clin Proc. n May 202
wnloaded for Anonymous User (n/a) at Aalborg Hospital from Clinica
For personal use only. No other uses without permission. Copyright ©earlier publications, the present study re-
ported that in this high-risk diabetes sub-
group, apixaban and dabigatran were
associated with a lower risk of MB compared
with warfarin and rivaroxaban.26,35,36
This retrospective observational study
has several limitations. First, only statistical
associations could be concluded, not causal
relationships. Although cohorts were
matched through PSM, there were potential
residual confounders. This limitation is espe-
cially important for interpreting NOAC and
NOAC comparison results, which are
intended for hypothesis generation, given
the lack of head-to-head trials. Second,
because of the nature of claims studies,
outcome measures could only be based on
ICD-9-CM codes without further adjustment
with precise clinical criteria. In addition, the
dose of warfarin and laboratory values, such
as INR measurements, are not available in
the data set, so the time in therapeutic range
for patients prescribed warfarin was indeter-
minable. Nonetheless, the inclusion of pa-
tients with potentially poorer quality
control of warfarin therapy in everyday clin-
ical practice may enable the study findings to
better reflect real-world situations. In0;95(5):929-943 n https://doi.org/10.1016/j.mayocp.2019.05.032
www.mayoclinicproceedings.org
lKey.com by Elsevier on August 26, 2020.
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SAFETY AND EFFECTIVENESS OF ORAL ANTICOAGULANTSaddition, a previous study found that PSM
using claims-defined baseline characteristics
was sufficient in balancing mean INR and
INR categories across post-PSM warfarin co-
horts matched to different NOACs (dabiga-
tran, rivaroxaban, and apixaban).37 Given
our limited ability to clinically characterize
diabetes type and severity (represented by dia-
betes medications and complications) because
of our reliance on claims data, we could not
further assess whether our findings would
be different by type and severity of diabetes,
such as duration of diabetes or hemoglobin
A1c levels.
10,11 Type 1 diabetes occurs at a
younger age and type 2 diabetes occurs at
an older age and has a higher prevalence of
AF. Previous studies have found that stroke
risk may be higher in type 1 diabetic patients,
but a recent study of patients with NVAF did
not find an association between type of dia-
betes and risk of thromboembolism.38-40 We
are not able to assess the effect of the type
of diabetes in our study. Moreover, unob-
served heterogeneity may exist across the 5
data sources. Although some of the data sets
contain information from different insurance
plans that do not overlap at the plan level,
others are employer-based claims data sets
that may contain duplicate patient records
when pooled together. However, the number
of such duplicates is likely to be lowdon
the basis of a published estimate of 0.5%d
and therefore unlikely to have any significant
effect on the results.41 Finally, the results may
not reflect the overall population with NVAF
in the United States, because the study did not
include uninsured patients and those solely
covered by other public health insurance
plans.
CONCLUSION
This study, the largest observational study of
NVAF with concomitant diabetes, reports
that NOACs were associated with variable
rates of stroke/SE and MB compared with
warfarin and compared with each other.
These findings supplement the information
from the NOAC randomized controlled trials
and may support future studies on patients
with NVAF and concomitant diabetes to pro-
vide clinicians with a better understandingMayo Clin Proc. n May 2020;95(5):929-943 n https://doi.org/10.101
www.mayoclinicproceedings.org
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betic patients in routine clinical practice.SUPPLEMENTAL ONLINE MATERIAL
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